Arcturus Therapeutics Holdings Inc. 8-K

What Happened

• Arcturus Therapeutics Holdings Inc. filed an 8-K reporting that on June 26, 2026 its wholly‑owned subsidiary Arcturus Therapeutics, Inc. entered into a Master Services Agreement (MSA) with Thermo Fisher Scientific Inc. and a Project Addendum with Patheon UK Limited to provide CDMO and CRO services for ARCT-032, Arcturus’s investigational mRNA therapeutic for cystic fibrosis. The Company furnished a related press release on July 2, 2026.

Key Details

• Thermo Fisher will contribute up to $40.0 million of clinical manufacturing services for ARCT-032; Arcturus will engage PPD, Inc. (Thermo Fisher’s CRO affiliate) for up to $40.0 million in CRO services.
• Upon regulatory approval of ARCT-032, Thermo Fisher would receive exclusive commercial manufacturing rights for a specified duration under a commercial supply agreement to be negotiated in good faith.
• The MSA has an initial five‑year term from its effective date and automatically renews for successive one‑year periods unless either party gives at least 90 days’ prior written notice of non‑renewal.
• The Project Addendum covers technical transfer, engineering batches, manufacture of clinical trial and process qualification materials, open‑label extension batches, drug product fill/finish, product release, and stability studies.

Why It Matters

• The agreements establish a named development and manufacturing partner for ARCT‑032, committing defined CDMO and CRO capacity and budgeted services that are material to the program’s development path. The MSA also sets a framework for exclusive commercial supply by Thermo Fisher if ARCT‑032 is approved, with final commercial terms to be negotiated. Investors should note the $40M service commitments, the five‑year contract framework, and the planned filing of the full agreements as exhibits to Arcturus’s Form 10‑Q for the quarter ending June 30, 2026.